Fig. 2From: Comparison of the outcomes between sorafenib and lenvatinib as the first-line systemic treatment for HBV-associated hepatocellular carcinoma: a propensity score matching analysisOverall survival. Kaplan–Meier estimates of overall survival by treatment group. OS, overall survival; HR, hazard ratio; CI, confidence intervalBack to article page